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Research in context  
Evidence before this study 
Airflow capacity peaks in the early 20s in healthy people, then slowly declines with age. We 
identified relevant studies through the Adults born Preterm International Collaboration (APIC; 
www.apic-preterm.org), and from searching PubMed and Embase for studies of lung function in 
late adolescence or early adulthood in humans using terms “respiratory function OR lung 
function OR spirometry” combined with “preterm OR low birth weight” (searched May, 2016).  
Individual cohort studies of airflow capacity in late adolescence or early adulthood of survivors 
born very preterm (VP; <32 weeks’ gestational age) or very low birthweight (VLBW; <1500 g) 
have mainly reported reductions in airflow, particularly in those who had bronchopulmonary 
dysplasia (BPD) in the newborn period, but there is variation in the size of the reductions. 
Moreover, airflow trajectory after the early 20s is unclear. 
Added value of this study 
VP/VLBW survivors are not reaching the normal peak of airway capacity in their early 20s. The 
reductions in airflow capacity in VP/VLBW survivors in early adulthood are substantial, with 
more than a 4-fold increase in the numbers with values in worrying clinical ranges compared with 
term-born or normal birthweight survivors. Moreover, there is no evidence to suggest that the rate 
of change in airway capacity after the early 20s is better in VP/VLBW survivors compared with 
controls, and it may even be worse. VP/VLBW survivors who had BPD in the newborn period 
have even worse airflow capacity that those who did not have BPD.   
Implications of all available evidence 
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Adult physicians, whether they be in general practice or are specialists, need to be aware that 
more infants born VP/VLBW are now surviving into adulthood, and many will present with 
symptoms of airflow obstruction. Adult physicians should know the gestational age and birth 
weight of their patients with respiratory disease and be aware that patients who were born 







Background: Maximal expiratory airflow peaks in the early 20s, then gradually declines with 
age. The pattern of airflow through adulthood for individuals born very preterm (VP; <32 weeks’ 
gestation) or very low birthweight (VLBW; <1501 g) is unknown.  
Objectives: To compare maximal expiratory airflow in late adolescence/early adulthood in 
survivors born VP/VLBW with normal birthweight (>2499 g) or term-born controls, and 
determine perinatal and demographic associations with airflow in VP/VLBW survivors. 
Data sources: Cohort studies, mostly from the pre-surfactant era  
Study eligibility: Survivors born VP/VLBW and controls beyond 16.0 years of age  
Study appraisal and synthesis methods: Studies were identified through the Adults born 
Preterm International Collaboration and searching PubMed and Embase. Individual participant 
data on expiratory flow variables (forced expired volume in 1 second (FEV1), forced vital 
capacity (FVC), FEV1/FVC, and flow between 25%-75% of the vital capacity (FEF25-75%)) were 
converted to z-scores and analysed using generalised linear mixed models in a one-step approach.   
Results: There were 935 VP/VLBW and 722 controls from eleven individual cohorts; the mean 
age at testing was 21 (range 16-33) years. Controls had mean z-scores close to the expected 
values of zero (e.g., zFEV1 -0.06 [SD 1.03]), but VP/VLBW survivors were substantially lower 
(zFEV1 -0.81 [SD 1.33]; mean difference -0.78, 95% confidence interval [CI] -0.96, -0.61)). 
Moreover, approximately one-quarter of VP/VLBW participants had values less than the 5th 
centile for most variables, more than four-fold higher than controls (e.g., FEV1; VP/VLBW 24% 
[221/935], controls 7% [50/722], odds ratio 4.16, 95% CI 2.99, 5.78). The trajectory of airflow 
was no better in 117 VP/VLBW participants than in 53 controls with paired data at 18 and 25 
years. Among VP/VLBW survivors, better airflow was associated with antenatal corticosteroids, 
female sex, and no history of bronchopulmonary dysplasia; zFVC was higher in smokers. 
Conclusions: VP/VLBW survivors are at risk of not reaching their full airway growth potential 
in early adulthood, suggesting an increased risk of chronic obstructive pulmonary disease in later 
adulthood. 
Funding: National Health and Medical Research Council; University of Bergen, Western 
Norway Regional Authority; National Institute for Health Research, UK; Stichting 
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Astmabestrijding; St. Olav’s Hospital’s Research Fund; Academy of Finland; European 




Maximal expiratory airflow, which reflects airway growth, increases throughout childhood, peaking in 
the early 20s, and then slowly declines with age, with only small differences in the pattern of change 
with age between males and females.1 In elderly people with normal lung function the gradual decline 
in airflow with age is not a concern because they are likely to die from other causes before airflow 
declines to a point where individuals become symptomatic. However, an excessive rate of decline in 
airflow, such as may occur with tobacco smoking, is concerning, and leads to higher rates of chronic 
obstructive pulmonary disease (COPD) in adulthood.2 Similarly, individuals who do not reach their 
expected peak airflow might also become symptomatic earlier in adulthood than expected. 
The development of prenatal and neonatal care in recent decades has brought about dramatic 
improvements in the prognosis for infants born very preterm (VP; <32 weeks’ gestation) or with very 
low birthweight (VLBW; <1501 g), who constitute 1-2% of all births worldwide.3 Many of these “new 
survivors” have reached adulthood: the number of VP/VLBW survivors born in the 1970s and 1980s is 
estimated as over half a million in the USA alone.4,5 Therefore, questions related to their health are 
increasingly relevant. VP/VLBW survivors have more airway obstruction in childhood than those born 
of normal birthweight NBW; (>2499 g), a difference that persists into early adulthood.6-14 Those who 
had bronchopulmonary dysplasia (BPD) in the newborn period have even more airway obstruction than 
do VP/VLBW survivors without BPD.6-8,10,11,13,14 Apart from BPD, the relationships of airflow in 
VP/VLBW survivors in early adulthood with other perinatal events, such as antenatal corticosteroids, 
gestational age, fetal growth, or sex, or with tobacco smoking are unclear, partly because existing 
studies are based on single cohorts, with limited power. Moreover, the rate of decline in airflow with 
age beyond the peak of maximal airflow capacity in VP/VLBW survivors in adulthood is unknown.  
In this individual patient data (IPD) meta-analysis we aimed to compare airflow in late 
adolescence and early adulthood in survivors born VP/VLBW mostly in the pre-surfactant era 
with NBW or term-born controls, including the trajectory of airflow after the expected peak in 
the early 20s, and to identify perinatal and demographic risk and protective associations with 
airflow among preterm survivors. It was hypothesized that VP/VLBW survivors would have 
worse airflow than controls, and that, within the VP/VLBW group, those who had BPD and those 





Through the Adults born Preterm International Collaboration (APIC; www.apic-preterm.org), we 
identified studies potentially suitable for inclusion in an IPD meta-analysis. APIC was formed in 
2011 and comprises research groups from around the world with health data on cohorts of 
participants born VP/VLBW who had been followed into late adolescence or early adulthood.15 
We also searched PubMed and Embase for studies of lung function in late adolescence or early 
adulthood in humans using terms “respiratory function OR lung function OR spirometry” 
combined with “preterm OR low birth weight” (searched May, 2016).   
Inclusion Criteria for Studies 
Inclusion criteria comprised the following: cohort studies of survivors born VP/VLBW, where 
NBW or term-born controls were also studied, and where the age of participants when measuring 
expiratory flows was 16 years or older. We did not include highly-selected cohorts, such as just 
those with BPD, or cohort studies where all birthweights or gestational ages were studied, but 
few were born VP/VLBW, or where it was impossible to determine whether those studied 
represented the sample of all possible survivors from either the hospitals or geographical regions 
concerned. Methods and criteria for selection of controls varied from study to study 
(Supplementary Table 1). 
Data Requested 
Perinatal data, including year of birth, antenatal corticosteroid therapy, gestational age, 
birthweight, sex, and bronchopulmonary dysplasia (BPD) were requested from each study. Data 
on maternal smoking during pregnancy were missing for approximately one-third of the 
participants (33%; 540/1657), so it was only considered as a potential confounder in secondary 
analyses comparing differences in flow rates between VP/VLBW and control groups. 
Birthweight z-scores were computed for age and sex, relative to the British Growth Reference.16 
BPD definition varied between studies, from either oxygen dependency at 28 days, with or 
without chest X-ray changes consistent with Northway’s classification,17 to oxygen dependency 
at 36 weeks’ postmenstrual age.18 At the time of lung function assessment, a history of current 
tobacco smoking was obtained. 
Expiratory Flows 
In all cohorts, forced expiratory flow was measured using spirometry according to the American 
Thoracic Society and European Respiratory Society guidelines,19 or equivalent guidelines at the 
time that the cohorts were studied. The following values were obtained; forced expired volume in 
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1 second (FEV1), forced vital capacity (FVC), and the ratio of the two (FEV1/FVC), and the 
forced expiratory flow at 25%–75% of FVC (FEF25%–75%). Two studies did not measure FEF25%–
75%.
10,12  We did not collect data on bronchodilator responses because they were not measured in 
all studies, and in some studies that did, they were measured only on subsets of participants with 
low expiratory flows..  
Expiratory flows were converted to z-scores for age, height, sex and ethnicity, relative to the 
Global Lung Initiative 2012 reference values.20 The proportions with clinically important values 
for airflow <5th percentile were computed. 
Governance 
Participants in each cohort had been recruited after providing informed consent and each study 
had been approved by the appropriate Institutional Review Boards (IRBs). When required, 
investigators obtained separate permission from their IRBs to submit data for the IPD meta-
analysis. Written data transfer agreements were obtained between the Murdoch Children’s 
Research Institute, where the data were pooled and analysed, and the other centres which 
provided data. Non-identifiable data were then transferred for analysis.   
Data Analysis 
Data were analysed using Stata 15.1.21 Analyses were conducted using generalised linear mixed 
models with robust standard errors in a one-step approach. For each dependent variable we 
considered both a random intercept model (including a random effect for study site) as well as a 
random intercept and slope model (by adding a random effect to allow for different relationships 
between VP/VLBW and control groups among the different study sites) and compared the 
different models by the change in likelihood ratio chi-square between the two. We also attempted 
to add a third random effect to account for more than one measurement taken at two different 
ages at two study sites, but in some analyses the models would not converge with the third 
random effect, so it was not included in any analyses. Expiratory flow data from VP/VLBW 
participants were compared with controls by the inclusion of a fixed effect for group. Expiratory 
flow data from VP/VLBW participants were compared with controls by the inclusion of a fixed 
effect for group.  
The proportions with low values for each expiratory value were also contrasted between groups 
using mixed models, with a random effect for study site and random effect to allow for different 
9 
 
relationships between VP/VLBW and control groups among the different study sites, as well as a 
fixed effect for group. 
To establish the trajectory of decline after the expected peak of maximal airway capacity in 
VP/VLBW survivors, the relationships of expiratory flows with age at testing were repeated with 
the analyses limited to those participants with ages >21 years. Also, in the two studies where the 
same participants were tested at two ages (approximately 18 and 25 years, respectively), the 
differences in airway capacity between the ages were analysed using mixed models with a 
random effect for the two different sites, with and without adjusting for the baseline expiratory 
flow values for each variable. Within the VP/VLBW group univariable relationships of 
expiratory flows with antenatal corticosteroids, gestational age, birthweight z-score, sex, BPD, 
smoking, year of birth, and age at testing were explored, and then all variables were entered in 
multivariable analyses to determine the independent associations of these variables with 
expiratory flows.   
The funding sources had no role in the study design, collection, analysis or interpretation of the 
data, or the writing of the report.  LD had access to the raw data. The corresponding author had 
full access to all of the data and the final responsibility to submit for publication. 
 
Results 
Eleven cohorts met the inclusion criteria, as shown in Table 1, listed in chronological order by 
year of birth.6-14,22,23 In two cohorts, measurements were obtained twice from some participants; 
at approximately 18 years of age,11,22,23 and again at approximately 25 years of age.6,11,23 One site 
recruited cohorts from two different eras.11 A repeat literature search in January 2018 did not 
identify any additional potentially eligible cohorts. Across the 11 cohorts there were 935 preterm 
and 722 controls with airflow data available for analysis. The studies were from six different 
high-income countries, approximately one-half were regional studies, years of birth ranged from 
1977 to 1993, and the age when studied ranged from 16 to 33 years. Most of the 1657 
participants in both birth groups were Caucasian (96.1%; n=1592), followed by South-East Asian 
(1.8%; n=30), other/mixed (1.5%; n=25), and black (0.5%; n= 9); only 0.1% (n=1) were North-
East Asian.   
Among the VP/VLBW participants, rates of antenatal corticosteroid therapy ranged from 6% to 
71% across the cohorts, mean gestational ages and birthweights fell over time, just under 50% 
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were male, and surfactant treatment was uncommon until births in the 1990s (Table 2).  Rates of 
smoking ranged from 3% to 42%. 
1.  VP/VLBW compared with controls 
There was some evidence of improved model fit with the random intercepts and slope models 
compared with the random intercept only models for zFEV1 and zFEF25-75%, but not for zFVC or 
for zFEV1/FVC (Supplementary Table 2).  Importantly, the conclusions regarding the differences 
between VP/VLBW and control groups were unchanged, with little change in the estimates of the 
differences between the two groups for the two models (Supplementary Table 2).  We 
subsequently report data only from models with both the random intercepts and random slopes 
for all outcomes for consistency. 
Controls had mean z-scores for expiratory flows close to the expected values of zero, but 
VP/VLBW survivors had substantially lower mean values for all expiratory flows of 
approximately -0.75 SD for zFEV1, zFEV1/FVC, and zFEF25-75%, whereas zFVC was only -0.25 
SD lower (Table 3).  Maternal smoking in pregnancy was associated with reductions in all 
airflows except zFVC; adding maternal smoking to the models changed the differences between 
VP/VLBW and control groups by less than ±0.03 SD and altered no conclusions.  
Approximately one-quarter of VP/VLBW participants had values less than the 5th centile for most 
flow variables, and proportions for all variables were substantially higher than in controls, where 
the proportions less than the 5th centile were close to the expected value of 5% (Table 3).   
There was little heterogeneity between the studies, as assessed by the I2 statistic for any of the 
expiratory flow variables; zFEV1 2.0%, zFVC 0.4%, zFEV1/FVC 0.2% and zFEF25-75% 5.7%.  
Forest plots for each variable showing results for individual studies and the overall summaries are 
shown in Supplementary Figure 1.  
Most cohorts were selected by birthweight only and hence most of the VP/VLBW group were 
VLBW (99%; 927/935).  However, most were also VP (90%; 841/935).  There was little 
difference in summary values for expiratory flow variables regardless of the way the VP/VLBW 
cohort was categorised (Supplementary Table 3).   
There were 669 participants assessed at ages >21.0 years; 360 were born VP/VLBW and 309 
were controls. Among this group of older participants, there was evidence that the rate of change 
with age in z-scores was lower in the VP/VLBW participants compared with controls for zFEV1 
(coefficient -0.06, 95% CI -0.10, -0.01; interaction p=0.025;) and zFVC (coefficient -0.06, 95% 
11 
 
CI -0.10, -0.02; interaction p=0.001), but not for zFEV1/FVC (interaction p=0.98) or zFEF25-75% 
(interaction p=0.16). Although the interaction term was significant for zFEV1, there was little 
evidence for any associations with age at testing in either subgroup alone (VP/VLBW coefficient 
0.00, 95% CI -0.03, 0.03; p=0.93; controls coefficient 0.02, 95% CI -0.01, 0.05; p=0.14).  In 
contrast, for zFVC the evidence for a positive association with age at testing was strong among 
the controls (coefficient 0.05, 95% CI 0.03, 0.08; p<0.0001), but there was little evidence for any 
association within the VP/VLBW group (p=0.84).   
There were 117 VP/VLBW participants and 53 controls who had airflow measured on two 
occasions; at 18 years and 25 years of age. zFEV1 increased between 18 and 25 years in both 
groups by a similar amount (Table 4). zFVC increased between 18 and 25 years in both groups, 
but less so in the VP/VLBW group, a difference which was sustained after adjusting for the 
baseline value of zFVC. zFEV1/FVC decreased between the two ages more in the controls, but 
the differences between the groups were not substantial, before or after adjustment for the 
baseline value of zFEV1/FVC.   
2.  Perinatal and demographic associations within the VP/VLBW group 
There was evidence that gestational age was positively associated with all flow rates, and that 
zFVC was higher with year of birth and age of testing, but the evidence disappeared in the 
multivariable analyses (Figure 1). There was strong evidence on both univariable and 
multivariable analysis that zFEV1 was higher with antenatal corticosteroids, but lower in males 
and in those who had BPD, that zFVC was higher with antenatal corticosteroids and in smokers, 
but lower in those who had BPD, and that both zFEV1/FVC and zFEF25-75% were lower in males 
and in those who had BPD. 
 
Discussion 
The major findings of this IPD meta-analysis are that late adolescents/young adults born 
VP/VLBW had substantially lower airflow rates and they were over four-fold more likely to have 
reduced values that were clinically important than did controls. Among VP/VLBW survivors, 
there were strong independent negative relationships of airflow with male sex and BPD, and 
positive relationships with antenatal corticosteroids. An unexpected finding was that zFVC was 
higher in smokers. As the range of ages of assessment included the age when peak lung growth 
normally occurs in the early 20s it is apparent that infants born VP/VLBW are not achieving their 
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full airway growth potential, since they have substantially lower z-scores for all expiratory flows. 
In analyses restricted to those over 21 years of age, the rate of change of airflow with age was 
less in VP/VLBW participants compared with controls, suggesting that the rate of decline in later 
adulthood in VP/VLBW survivors might be higher than in controls. Even if the maximal 
expiratory airflow declines at a normal rate with age in VP/VLBW adults, proportionally more 
are destined to develop COPD later in life than controls; 26% of people in a normal population 
will develop COPD if they fail to reach a normal airflow plateau in early adulthood.24 If their 
maximal expiratory airflow declines at a faster rate, even more adults born VP/VLBW will 
develop COPD; however, it is too soon to know for certain what the rate of decline might be 
throughout adulthood for those born VP/VLBW.  
The overall results are consistent with data from the individual studies of young adults who were 
born VP/VLBW compared with controls, and within VP/VLBW cohorts comparing those who 
did and did not have BPD.6-14 What the IPD has allowed is more precise estimates of effect sizes, 
assessment of the rate of decline in airflow capacity beyond the early 20s, and an investigation of 
other independent associations of flow rates with variables that is not possible within a typical 
meta-analysis of cohort studies. We can confirm that the differences between VP/VLBW 
survivors and controls are large, and that more than four-fold have values in worrying clinical 
ranges (<5th centile) compared with controls. Moreover, survivors born VP/VLBW who had BPD 
have even worse expiratory flow rates. The associations with sex and antenatal corticosteroids 
have not been previously reported in cohorts of survivors born VP/VLBW in adulthood, although 
one study combining 10-year-olds and 17-year-olds did report improved airflow with antenatal 
corticosteroid exposure.25  
To the best of our knowledge we have included all cohort studies of VP/VLBW participants who 
met our eligibility criteria. Four cohort studies were not included. Northway et al26 studied 26 
highly-selected individuals with BPD, 26 preterm individuals without BPD and 53 term controls, 
born in the early era of assisted ventilation from 1964 to 1973. Because the mean birthweight was 
>1800 g and the mean gestational age was >33 weeks in the preterm groups, few individuals 
would have been VP/VLBW. This study was also excluded because their results are unlikely to 
be typical of the era when assisted ventilation was more routine, from the mid-1970s onwards. 
Wong et al27 included only 21/133 survivors with BPD from one hospital born between 1980-
1987, and there were no non-BPD preterm children or controls. In the study of Landry et al28 
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participants were recruited from births in Quebec between 1987-1993 into one of four groups 
with sample sizes of approximately 30 each based on gestational age and respiratory morbidity 
criteria. However, it was not possible to determine how many infants might have been eligible 
from the province of Quebec within each group over the time of birth of the participants. 
Moschino et al29 assessed lung function from childhood to 24 years of age in 17 participants who 
had BPD and who were born over a 3-year period in 1991-1993; there were no non-BPD 
participants or term-born controls; hence the study was excluded. We also did not include 
studies30,31 where survivors of all birthweights and gestational ages were studied because so few 
would have been VP/VLBW relative to the number of potential controls. 
The association of higher values for zFVC, but no other expiratory flows, in smokers than non-
smokers, in both VP/VLBW participants and controls, was unexpected.  Others have, however, 
reported that adolescents and young adults who smoke have higher FVC than non-smokers.32 
Why zFVC might be higher in smokers is unclear, but, whatever the explanation, the finding 
needs replication in survivors born VP/VLBW. More importantly, participants in the current 
studies should have airflow measured in later life to determine longer-term effects of smoking on 
expiratory flows in those born VP/VLBW. 
In a follow-up study of 5718 men born in Hertfordshire, England during 1911-30, lower 
birthweight, and presumably increasing prematurity, was associated with higher death rates from 
COPD, and worse respiratory function at 59-70 years of age.33 In another study of 2984 survivors 
born in Sweden from 1925 to 1949 with a birthweight <2100 g or gestational age <35 weeks, 
COPD was more common with either diminishing birthweight or earlier gestational age.34 
Current studies of expiratory airflow in preterm survivors of modern perinatal/neonatal intensive 
care have only been in participants aged up to their early 30s, which is too early to detect high 
rates of COPD, or of death caused by COPD.  
Several recent studies have reported that trajectories of expiratory flows track from childhood 
into adulthood, in one report into the 50s,35 and in the other report into the 20s.36  However, these 
studies would have had few VP/VLBW participants and hence tracking of expiratory flows of 
VP/VLBW survivors from childhood into adulthood remains to be determined. 
There are a number of limitations of the current study. The data are largely derived from cohorts 
born before exogenous surfactant was available from the early 1990s and are relevant to the 
thousands of survivors born VP/VLBW before the early 1990s who are now adults. The rate of 
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change in airflow capacity in adulthood among survivors born VP/VLBW in the surfactant era 
remains to be established. The protocols for each study varied in inclusion criteria, ages at 
assessment, definitions of BPD, and respiratory function tests performed, resulting in 
heterogeneous cohorts being studied. The NICHD definition of BPD was reported in 2001,18 
which was after the birth of all of the participants in the current study. The data required to define 
BPD as per the NICHD definition were not available for all cohorts and hence it could not be 
determined retrospectively.  Variation between studies can be avoided by agreeing on common 
protocols and performing prospective individual participant meta-analyses, which should be the 
way forward in future studies of VP/VLBW survivors. However, variation between the studies is 
also a strength because the reductions in airflow between VP/VLBW and control cohorts are 
consistent across the various studies, and hence the conclusions are widely applicable to 
VP/VLBW survivors from the same era who have not been studied. We could not analyse data 
that were not collected consistently across all studies, such as bronchodilator responses to 
determine the reversibility of airway obstruction, passive smoke exposure in childhood, pack-
years of active smoking, or respiratory illnesses through childhood. We also had substantial 
missing data on maternal smoking; adding it as a covariate had little effect on any conclusions 
concerning differences between VP/VLBW and control groups. We did not add asthma as a 
covariate to any group differences between VP/VLBW and control groups as asthma might lie 
along the casual pathway between VP/VLBW and poor expiratory airflow. We focused our 
analyses on VP and VLBW participants combined; however, summary results reported for either 
VP alone or VLBW alone were almost identical. Finally, we do not have data on expiratory flow 
across a broad range of adult ages to determine the true longitudinal trajectory of expiratory flows 
in VP/VLBW survivors into late adulthood, which has occurred in part because so few 
VP/VLBW participants survived into adulthood before the time of birth of the cohorts included in 
this study. However, given the clear reductions in airflow in VP/VLBW survivors compared with 
controls up to the early 30s in the current study, particularly in those who had BPD, follow-up 
into later adulthood of our cohorts is mandatory. 
What can be done?  Given the worse expiratory flow rates among survivors born VP/VLBW who 
had BPD, we must try to reduce rates of BPD in the newborn period. However, rates of BPD may 
be increasing and not decreasing in survivors born <28 weeks’ gestational age in more recent 
eras, and their expiratory flow rates in childhood may be deteriorating,37 which, if true, will only 
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exacerbate the problem of airway obstruction in adulthood in survivors born VP/VLBW from 
more recent eras. Adult physicians, be they general practitioners or specialists, should be aware 
that more VP/VLBW infants are surviving into adulthood, and that they are more likely to 
present with respiratory problems than those born at term, particularly those who had BPD. 
Physicians should obtain a perinatal history, including birthweight, gestational age and BPD, 
when assessing adults with airway disease, and be aware that those who were VP/VLBW or who 
had BPD are likely to be at higher risk of later chronic obstructive pulmonary disease. In the 
absence of any bronchodilator data to the contrary, it is possible that survivors born VP/VLBW 
may have fixed airway obstruction that may not respond to any COPD treatments, such as 
bronchodilators, and therefore therapeutic approaches in VP/VLBW survivors may need to differ 
from other, e.g., smoking-related, patients.  Notwithstanding the higher zFVC in smokers in the 
short-term in the current study, avoidance of smoking in the longer-term is paramount to 
avoiding COPD in later life. 
In conclusion, survivors born VP/VLBW from the era of modern intensive care are not reaching 
their full airway growth potential in early adulthood: already at that time they were more than 
four-fold more likely to have clinically important reduced values for airflow than NBW or term-
born controls. Those who had BPD in the newborn period are even more disadvantaged. Unless 
the rate of decline in airflow with age is lower in adult VP/VLBW survivors compared with what 
normally occurs, many will develop COPD in later adult life. 
 
Author contributions 
LD: conception and design of the study, data collection, analysis and interpretation, drafting and 
revising the article, and approval of the final manuscript as submitted. 
SA: data collection and interpretation, revising the article, and approval of the final manuscript as 
submitted. 
AB: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript as submitted. 
JLYC: conception and design of the study, data analysis and interpretation, drafting and revising 
the article, and approval of the final manuscript as submitted. 
16 
 
HC: data collection and interpretation, revising the article, and approval of the final manuscript as 
submitted. 
KAIE: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript as submitted. 
AG: data collection and interpretation, revising the article, and approval of the final manuscript 
as submitted. 
TH: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript, as submitted. 
PH: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript as submitted. 
EK: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript as submitted. 
KJL: data analysis and interpretation, revising the article, and approval of the final manuscript as 
submitted. 
LMcG: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript as submitted. 
IN: data collection and interpretation, revising the article, and approval of the final manuscript as 
submitted. 
PN-G: data interpretation, revising the article, and approval of the final manuscript as submitted. 
SS: data collection and interpretation, revising the article, and approval of the final manuscript as 
submitted. 
MV: conception and design of the study, data collection and interpretation, revising the article, 
and approval of the final manuscript as submitted. 
EJLEV: conception and design of the study, data collection and interpretation, revising the 
article, and approval of the final manuscript as submitted. 
17 
 
Sources of support 
Grants from the National Health and Medical Research Council of Australia (Program Grant 
#606789; Project Grant #491246; Centre of Clinical Research Excellence #546519; Centre of 
Research Excellence #1060733; Career Development Fellowship #1141354 to JC and 1127984 to 
KJL); University of Bergen and Western Norway Regional Authority; National Institute for 
Health Research, UK, Senior Investigator to AB; de Stichting Astmabestrijding; St. Olav’s 
Hospital’s Research Fund; Academy of Finland (grants 127437, 129306, 130326, 134791, 
263924, 274794 and 288966), European Commission (H2020 award SC1-2016-RTD-733180 
RECAP), Novo Nordisk Foundation, Foundation for Pediatric Research, Foundation for 
Cardiovascular Research, Foundation for Diabetes Research, Sigrid Juselius Foundation, Signe 
and Ane Gyllenberg Foundation, Juho Vainio Foundation, and the Yrjö Jahnsson Foundation; 
NICHD contracts No. 1-HD-4-2803 and No. 1-HD-1-3127; the Victorian Government’s 
Operational Infrastructure Support Program. The funding sources had no role in the study design; 
in the collection, analysis, and interpretation of data; in the writing of the report; or in the 
decision to submit the paper for publication. 
Conflicts of interest 
Dr L McGarvey reports personal fees from Merck, grants from GSK, Boehringer Ingelheim, 
Chiesi, Novartis, Astra Zeneca, outside the submitted work. 
Dr E Kajantie reports grants from Academy of Finland (127437, 129306, 130326, 134791, 
263924, 274794 and 288966), grants from European Commission (H2020 award SC1-2016-
RTD-733180 RECAP), grants from Novo Nordisk Foundation, grants from Foundation for 
Pediatric Research, grants from Foundation for Cardiovascular Research, grants from  
Foundation for Diabetes Research, grants from Sigrid Juselius Foundation, grants from Signe and 
Ane Gyllenberg Foundation, grants from Juho Vainio Foundation, grants from Yrjö Jahnsson 
Foundation, during the conduct of the study, but outside the submitted work. 




1. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. 
Lancet Respir Med 2013; 1(9): 728-42. 
2. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of 
chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 
2009; 180(1): 3-10. 
3. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm 
birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. 
Lancet 2012; 379(9832): 2162-72. 
4. Taffel SM. Trends in low birth weight: United States, 1975-85. Vital Health Stat 21 1989; (48): 1-30. 
5. Lee KS, Kim BI, Khoshnood B, et al. Outcome of very low birth weight infants in industrialized countries: 
1947-1987. Am J Epidemiol 1995; 141(12): 1188-93. 
6. Gibson AM, Reddington C, McBride L, Callanan C, Robertson C, Doyle LW. Lung function in adult 
survivors of very low birth weight, with and without bronchopulmonary dysplasia. Pediatr Pulmonol 2015; 50(10): 
987-94. 
7. Saarenpaa HK, Tikanmaki M, Sipola-Leppanen M, et al. Lung function in very low birth weight adults. 
Pediatrics 2015; 136(4): 642-50. 
8. Gough A, Linden M, Spence D, Patterson CC, Halliday HL, McGarvey LP. Impaired lung function and 
health status in adult survivors of bronchopulmonary dysplasia. Eur Respir J 2014; 43(3): 808-16. 
9. Narang I, Rosenthal M, Cremonesini D, Silverman M, Bush A. Longitudinal evaluation of airway function 
21 years after preterm birth. Am J Respir Crit Care Med 2008; 178(1): 74-80. 
10. Vrijlandt EJ, Gerritsen J, Boezen HM, Grevink RG, Duiverman EJ. Lung function and exercise capacity in 
young adults born prematurely. Am J Respir Crit Care Med 2006; 173(8): 890-6. 
11. Vollsaeter M, Roksund OD, Eide GE, Markestad T, Halvorsen T. Lung function after preterm birth: 
development from mid-childhood to adulthood. Thorax 2013; 68(8): 767-76. 
12. Evensen KA, Steinshamn S, Tjonna AE, et al. Effects of preterm birth and fetal growth retardation on 
cardiovascular risk factors in young adulthood. Early Hum Dev 2009; 85(4): 239-45. 
13. Vollsaeter M, Clemm HH, Satrell E, et al. Adult respiratory outcomes of extreme preterm birth. A regional 
cohort study. Ann Am Thorac Soc 2015; 12(3): 313-22. 
14. Doyle LW, Adams AM, Robertson C, et al. Increasing airway obstruction from 8 to 18 years in extremely 
preterm/low-birthweight survivors born in the surfactant era. Thorax 2017; 72(8): 712-9. 
15. Hovi P, Vohr B, Ment LR, et al. Blood pressure in young adults born at very low birth weight: Adults born 
Preterm International Collaboration. Hypertension 2016; 68(4): 880-7. 
16. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass 
index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17(4): 407-29. 
17. Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-
membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276(7): 357-68. 
18. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163(7): 1723-9. 
19. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 
2005; 26(1): 153-61. 
20. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age 
range: the global lung function 2012 equations. Eur Respir J 2012; 40(6): 1324-43. 
21. Stata/IC 15.1 for Windows. College Station, TX: Stata Corp LLC; 2018. 
22. Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very 
low birth weight subjects and lung function in late adolescence. Pediatrics 2006; 118: 108-13. 
23. Halvorsen T, Skadberg BT, Eide GE, Roksund OD, Carlsen KH, Bakke P. Pulmonary outcome in 
adolescents of extreme preterm birth: a regional cohort study. Acta Paediatr 2004; 93(10): 1294-300. 
24. Lange P, Celli B, Agusti A, et al. Lung-function trajectories leading to chronic obstructive pulmonary 
disease. N Engl J Med 2015; 373(2): 111-22. 
25. Halvorsen T, Skadberg BT, Eide GE, Roksund OD, Markestad T. Better care of immature infants; has it 
influenced long-term pulmonary outcome? Acta Paediatr 2006; 95(5): 547-54. 
26. Northway WH, Jr., Moss RB, Carlisle KB, et al. Late pulmonary sequelae of bronchopulmonary dysplasia. 
N Engl J Med 1990; 323(26): 1793-9. 
19 
 
27. Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe 
bronchopulmonary dysplasia. Eur Respir J 2008; 32(2): 321-8. 
28. Landry JS, Tremblay GM, Li PZ, Wong C, Benedetti A, Taivassalo T. Lung function and bronchial 
hyperresponsiveness in adults born prematurely. A cohort study. Ann Am Thorac Soc 2016; 13(1): 17-24. 
29. Moschino L, Stocchero M, Filippone M, Carraro S, Baraldi E. Longitudinal assessment of lung function in 
survivors of bronchopulmonary dysplasia from birth to adulthood. The Padova BPD Study. Am J Respir Crit Care 
Med 2018; 198(1): 134-7. 
30. Boezen HM, Vonk JM, van Aalderen WM, et al. Perinatal predictors of respiratory symptoms and lung 
function at a young adult age. Eur Respir J 2002; 20(2): 383-90. 
31. Suresh S, Mamun AA, O'Callaghan M, Sly PD. The impact of birth weight on peak lung function in young 
adults. Chest 2012; 142(6): 1603-10. 
32. Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung 
function in adolescent boys and girls. N Engl J Med 1996; 335(13): 931-7. 
33. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and 
childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. Bmj 1991; 
303(6804): 671-5. 
34. Brostrom EB, Akre O, Katz-Salamon M, Jaraj D, Kaijser M. Obstructive pulmonary disease in old age 
among individuals born preterm. Eur J Epidemiol 2013; 28(1): 79-85. 
35. Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD 
risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med 2018; 6(7): 535-44. 
36. Belgrave DCM, Granell R, Turner SW, et al. Lung function trajectories from pre-school age to adulthood 
and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies. 
Lancet Respir Med 2018; 6(7): 526-34. 
37. Doyle LW, Carse E, Adams AM, et al. Ventilation in extremely preterm infants and respiratory function at 
8 years N Engl J Med 2017; 377(4): 329-37. 
20 
 
Table 1.  Demographic characteristics of published studies with expiratory flow data reported in 
late adolescence/early adulthood in VP/VLBW survivors and controls. 
 














Doyle22  Australia hospital 1977-
82 
<1501 g 19 (18-
22) 
146 37 
Gibson6  Australia hospital 1977-
82 
<1501 g 26 (24-
29) 
87 19 
Saarenpaa7 Finland hospital† 1978-
85 
<1501 g 22 (18-
27) 
160 162 





































Evensen12 Norway regional 1986-
88 
<1501 g 18 (17-
19) 
38 63 
















*criteria for inclusion in original study; the numbers in this table relate only to those VP/VLBW 
or controls; †the only tertiary hospital within a geographical region 
VP=very preterm; VLBW=very low birth weight; BW=birthweight; GA=gestational age; 
BPD=bronchopulmonary dysplasia; w=weeks  
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Table 2.  Clinical characteristics of very preterm/very low birthweight participants by cohort. 
 
Study N  Antenatal 
cortico-
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0% (0) 23%* 
(33) 
34% (49) 

















4% (7) 18%* 
(29) 
38% (60) 


















































0% (0) 76%† 
(34) 
31% (14) 


















52% (16) 77%† 
(24) 
3 (1)  






40% (83) 37% 
(77) 
21% (43) 












Data are mean (SD), unless otherwise specified. BPD=bronchopulmonary dysplasia.  
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*BPD determined by oxygen requirement >28 days and chest X-ray consistent with Northway 
Stage 3 or 4 changes.17 †BPD determined by oxygen requirement >28 days ‡BPD determined by 
oxygen dependency at 36 weeks’ postmenstrual age; §reported for BPD subgroup only
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 Mean (SD) Mean (SD) Mean difference (95% CI)* P-value* 
zFEV1 -0.81 (1.33) -0.06 (1.03) -0.78 (-0.96, -0.61) <0.0001 
zFVC -0.38 (1.18) -0.15 (0.98) -0.25 (-0.40, -0.10) 0.001 
zFEV1/FVC -0.64 (1.35) 0.14 (1.10) -0.74 (-0.85, -0.64) <0.0001 
zFEF25-75% -0.95 (1.47) N=851 -0.04 (1.10) N=606 -0.88 (-1.12, -0.65) <0.0001 
 % <5th centile (n) % <5th centile (n) Odds ratio (95% CI)* P-value* 
FEV1 24% (221) 7% (50) 4.16 (2.99, 5.78) <0.0001 
FVC 11% (100) 6% (42) 2.12 (1.44, 3.14) <0.0001 
FEV1/FVC 23% (213) 6% (40) 5.09 (3.54, 7.30) <0.0001 
FEF25-75% 29% (247/851) 8% (46/606) 4.50 (2.82, 7.19) <0.0001 
*from individual participant data meta-analysis.  
VP=very preterm; VLBW=very low birth weight; CI=confidence interval; SD= standard 
deviation; FEV1=forced expired volume in 1 second; FVC=forced vital capacity; FEF25-75%=flow 
between 25%-75% of the vital capacity. 
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Table 4.  Changes in z-scores for expiratory flows between 18 and 25 years in the subset of 






























0.48 -0.16 (-0.37, 
0.06) 
0.16 




0.007 -0.32 (-0.52, -
0.11) 
0.002 




0.011 0.02 (-0.23, 0.27) 0.90 






0.39 -0.15 (-0.40, 
0.10) 
0.24 
*from individual participant data meta-analysis  
†adjusted for baseline value for expiratory flow 
SD= standard deviation; CI=confidence interval; FEV1=forced expired volume in 1 second; 
FVC=forced vital capacity; FEF25-75%=flow between 25%-75% of the vital capacity.
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Figure 1.  Associations of expiratory flows (z-scores) with perinatal and demographic variables 
among VP/VLBW participants. Mean differences and 95% confidence intervals for unit change 
in independent variable (except for Year of birth and Age – per 5 years). Solid line = univariable 
analyses; dashed line = multivariable analyses.  
CS=corticosteroids; BPD=bronchopulmonary dysplasia; SD= standard deviation; FEV1=forced 
expired volume in 1 second; FVC=forced vital capacity; FEF25-75%=flow between 25%-75% of 
the vital capacity. 
 
 
